Vanguard Group’s Editas Medicine EDIT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $16.8M | Buy |
8,208,068
+1,242,450
| +18% | +$3.59M | ﹤0.01% | 2699 |
|
|
2025
Q3 | $24.2M | Sell |
6,965,618
-193,874
| -3% | -$541K | ﹤0.01% | 2535 |
|
|
2025
Q2 | $15.8M | Sell |
7,159,492
-306,762
| -4% | -$502K | ﹤0.01% | 2668 |
|
|
2025
Q1 | $8.66M | Buy |
7,466,254
+643,256
| +9% | +$946K | ﹤0.01% | 2922 |
|
|
2024
Q4 | $8.67M | Buy |
6,822,998
+143,392
| +2% | +$365K | ﹤0.01% | 3032 |
|
|
2024
Q3 | $22.8M | Sell |
6,679,606
-1,352,998
| -17% | -$5.89M | ﹤0.01% | 2530 |
|
|
2024
Q2 | $37.5M | Sell |
8,032,604
-522,993
| -6% | -$2.95M | ﹤0.01% | 2262 |
|
|
2024
Q1 | $63.5M | Buy |
8,555,597
+93,740
| +1% | +$779K | ﹤0.01% | 2064 |
|
|
2023
Q4 | $85.7M | Sell |
8,461,857
-74,351
| -0.9% | -$653K | ﹤0.01% | 1940 |
|
|
2023
Q3 | $66.6M | Buy |
8,536,208
+370,734
| +5% | +$3.18M | ﹤0.01% | 2005 |
|
|
2023
Q2 | $67.2M | Buy |
8,165,474
+962,760
| +13% | +$8.39M | ﹤0.01% | 2057 |
|
|
2023
Q1 | $52.2M | Buy |
7,202,714
+329,591
| +5% | +$2.93M | ﹤0.01% | 2162 |
|
|
2022
Q4 | $61M | Buy |
6,873,123
+147,783
| +2% | +$1.62M | ﹤0.01% | 2078 |
|
|
2022
Q3 | $82.3M | Buy |
6,725,340
+89,730
| +1% | +$1.4M | ﹤0.01% | 1912 |
|
|
2022
Q2 | $78.5M | Sell |
6,635,610
-240,929
| -4% | -$3.23M | ﹤0.01% | 1961 |
|
|
2022
Q1 | $131M | Buy |
6,876,539
+202,642
| +3% | +$3.77M | ﹤0.01% | 1793 |
|
|
2021
Q4 | $177M | Buy |
6,673,897
+230,747
| +4% | +$7.94M | ﹤0.01% | 1682 |
|
|
2021
Q3 | $265M | Sell |
6,443,150
-40,782
| -0.6% | -$2.23M | 0.01% | 1419 |
|
|
2021
Q2 | $367M | Buy |
6,483,932
+136,178
| +2% | +$5.03M | 0.01% | 1204 |
|
|
2021
Q1 | $267M | Buy |
6,347,754
+522,868
| +9% | +$29.8M | 0.01% | 1412 |
|
|
2020
Q4 | $408M | Buy |
5,824,886
+116,850
| +2% | +$4.8M | 0.01% | 990 |
|
|
2020
Q3 | $160M | Sell |
5,708,036
-52,437
| -0.9% | -$1.71M | 0.01% | 1409 |
|
|
2020
Q2 | $170M | Buy |
5,760,473
+1,048,440
| +22% | +$27.4M | 0.01% | 1376 |
|
|
2020
Q1 | $93.4M | Buy |
4,712,033
+144,417
| +3% | +$3.64M | ﹤0.01% | 1565 |
|
|
2019
Q4 | $135M | Buy |
4,567,616
+248,851
| +6% | +$6.22M | ﹤0.01% | 1603 |
|
|
2019
Q3 | $98.2M | Buy |
4,318,765
+27,904
| +0.7% | +$691K | ﹤0.01% | 1741 |
|
|
2019
Q2 | $106M | Buy |
4,290,861
+355,256
| +9% | +$8.48M | ﹤0.01% | 1719 |
|
|
2019
Q1 | $96.2M | Buy |
3,935,605
+73,593
| +2% | +$1.67M | ﹤0.01% | 1770 |
|
|
2018
Q4 | $87.9M | Buy |
3,862,012
+132,433
| +4% | +$3.6M | ﹤0.01% | 1746 |
|
|
2018
Q3 | $119M | Buy |
3,729,579
+141,609
| +4% | +$4.58M | ﹤0.01% | 1720 |
|
|
2018
Q2 | $129M | Buy |
3,587,970
+571,862
| +19% | +$20.2M | 0.01% | 1647 |
|
|
2018
Q1 | $100M | Buy |
3,016,108
+247,705
| +9% | +$8.83M | ﹤0.01% | 1710 |
|
|
2017
Q4 | $85.1M | Buy |
2,768,403
+471,648
| +21% | +$11.9M | ﹤0.01% | 1805 |
|
|
2017
Q3 | $55.1M | Buy |
2,296,755
+119,609
| +5% | +$2.28M | ﹤0.01% | 1987 |
|
|
2017
Q2 | $36.5M | Buy |
2,177,146
+241,973
| +13% | +$4.36M | ﹤0.01% | 2174 |
|
|
2017
Q1 | $43.2M | Buy |
1,935,173
+618,789
| +47% | +$12.8M | ﹤0.01% | 2078 |
|
|
2016
Q4 | $21.4M | Buy |
1,316,384
+66,825
| +5% | +$1.01M | ﹤0.01% | 2396 |
|
|
2016
Q3 | $16.8M | Buy |
1,249,559
+716,590
| +134% | +$14.7M | ﹤0.01% | 2434 |
|
|
2016
Q2 | $13M | Sell |
532,969
-217,323
| -29% | -$7.33M | ﹤0.01% | 2522 |
|
|
2016
Q1 | $25.9M | Buy |
+750,292
| New | +$19.7M | ﹤0.01% | 2177 |
|
Other funds holding EDIT
N
Vanguard Group's EDIT Position: Q4 2025 in Review
Vanguard Group increased its Editas Medicine (EDIT) stake by 18% in Q4 2025, buying an estimated $3.59M and bringing the position to 8,208,068 shares worth $16.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2699.
Vanguard Group first reported a position in EDIT in Q1 2016 and has held it in 40 quarters since. The position peaked at $408M in Q4 2020. 197 funds tracked by Wall St. Rank hold EDIT as of Q4 2025.
- Vanguard Group held 8,208,068 shares of Editas Medicine worth $16.8M as of Q4 2025.
- Vanguard Group bought 1,242,450 Editas Medicine shares in Q4 2025, an estimated $3.59M.
- Editas Medicine made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2699 holding.
- Vanguard Group first reported a position in Editas Medicine in Q1 2016 and has held it in 40 quarters since.
- Vanguard Group's Editas Medicine position peaked at $408M in Q4 2020.
- 197 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.